COMP <GO>
IART vs SIBN // EV/EBITDA & P/E VALUATION
Integra LifeSciences Holdings Corporation (NASDAQ) VS. SI-BONE Inc. (NASDAQ) • 15-METRIC TALLY: IART 0
— SIBN 10
■ METRIC PARITY
LAST: $12.83 (+4.82%) • MKT CAP: $998.2M
valuation
—
LAST: $22.41 (+2.66%) • MKT CAP: $1.00B
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IART VS. SIBN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IART | SIBN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 50.90% | 79.60% | -28.70 | SIBN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -10.30% | -24.70 | SIBN | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.11% | -0.90% | -2.21 | SIBN | /fcf-yield <GO> |
| Operating Margin | -30.20% | -11.10% | -19.10 | SIBN | /operating-margins <GO> |
| Net Profit Margin | -31.60% | -9.40% | -22.20 | SIBN | /net-margins <GO> |
| Revenue Growth (YoY) | 1.50% | 20.20% | -18.70 | SIBN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.64 | 8.73 | -8.09 | SIBN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 6/9 | -2.00 | SIBN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.8 | 58.6 | -15.83 | SIBN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $998.2M | $1.00B | -$6.2M | SIBN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IART REV | SIBN REV | IART GROSS % | SIBN GROSS % | IART FCF | SIBN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.64B | $200.9M | 50.9% | 79.6% | -$31.1M | -$9.1M |
| FY 2024 | $1.61B | $167.2M | 54.8% | 79.0% | $25.0M | -$22.9M |
| FY 2023 | $1.54B | $138.9M | — | — | $140.0M | -$18.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IART // BETA —
SIBN // BETA —